Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules
about
High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction.A molecular and structural mechanism for G protein-mediated microtubule destabilization.Antibody-DM1 conjugates as cancer therapeutics.A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugsIdentification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells.T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.A novel MAPT mutation, G55R, in a frontotemporal dementia patient leads to altered Tau function.Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agentsNoscapine recirculates enterohepatically and induces self-clearance.Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 EpitopeSplenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer.The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancerTherapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.Immunotherapeutic strategies to target prognostic and predictive markers of cancer.Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer ModelsEvolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.Optimising the delivery of tubulin targeting agents through antibody conjugation.Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy.Experimental approaches in the treatment of multiple myeloma.Industrial natural product chemistry for drug discovery and development.Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs.Modeling the effects of drug binding on the dynamic instability of microtubulesInternalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.In vivo biotransformations of antibody-drug conjugates.Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.Emerging antibody-drug conjugates for treating lymphoid malignancies.Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates.Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment.Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine siteProtein based therapeutic delivery agents: Contemporary developments and challenges.Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.Promising therapies in multiple myeloma.Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity.Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial.Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
P2860
Q28543403-4DB0DC19-847E-46E3-B121-3609D5182DA7Q30498188-A416F03D-4C61-45EC-B91E-433AA8648582Q34177359-AA143354-DC6B-4503-A4D9-A61892D14EB5Q34281123-E9071BB6-9E10-4A91-BD85-3329122D5019Q34313834-C7FA50C8-935F-4B1E-9C52-14C76A598B67Q34998509-1C2CF32E-1F57-4389-937D-7E22AF9AA21AQ35006348-D9CB5839-897B-4FDB-99F9-BD918A2008BAQ35459059-EEE12DCC-E6B9-4CF2-A194-C52C91FEFAA9Q35737288-F7EA2625-3EE5-4DD5-A71E-91FD42D04199Q35893886-8B22CD19-AC5F-4216-93AF-E83D41DEDDCFQ36061613-0C84C7FA-018F-4475-A1FE-296EF8B565FBQ36256669-4BB5F4E7-ED94-4150-9539-D11915DDC144Q36745332-7BBB66EA-1E5C-4129-8653-40D414EEBD0DQ36824455-D019D40C-C29D-4AC4-B58C-4C7D7C2B84EDQ36958365-F5DCFE82-B6E2-4F1B-8A60-BE1A5EB37A68Q37126006-23507146-23B3-47AA-B6E5-DF478E7D74DBQ37447340-B080EA54-095F-4B3B-90C6-F1D7770112F9Q37585671-5D61CBA4-929F-4B6D-ABB4-A1449CA0CCEFQ37600390-93646DA7-E2F7-4F26-A38A-00615478B2F6Q38024991-C4587C29-E49C-4379-9F3C-32C474259CB5Q38073792-D4E9A086-56A4-49CE-941F-4B132F91888DQ38095958-A8F9B850-5F7A-4E16-8F16-B0C1F4FA59F5Q38154186-41ACB59F-6641-493E-91FC-800801744EBBQ38166831-704966A7-5DB2-4974-B17C-0AF78031B39BQ38341603-E2B74B28-E3CA-4C41-9987-8923B5E9F800Q38537257-C9249F4C-DBA5-4460-BB88-537C95544E79Q38557525-0E7D929E-0CC7-4A0B-ABF5-D7499EC2A3ECQ38624597-7916AAB6-F25B-469D-8C5F-F8CF46DEDD00Q38632313-F7F56426-4CF3-41C4-8E30-E95CA7EC1EB4Q38755443-5E79EC7E-6494-451A-800E-6C21A11ACDC7Q38922319-4EAED6A0-3369-460C-BDC6-BAF99C28D2D1Q39030222-880C164E-0D0E-4877-982F-A9EF607F74B6Q39079147-C773A39C-36D4-437A-923D-DC36A2D96A6AQ39273739-576C02E5-BFC4-46DB-BA93-2A8C0C647703Q39645683-15F5A4F9-92C1-4CCF-A5DF-2051C805A85CQ42581682-FFB96B6E-2B65-4FE4-B94F-86906991461EQ43525091-07605CA5-7778-448C-976F-42A3802A98EBQ44957894-DFCBA271-E4A0-4C81-A286-0981F4BF7422Q47136161-D8F895EB-CED5-407F-8661-8BD51946BBA2Q47661007-2E4C155C-BF4A-462F-9CFF-444A39EFE313
P2860
Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Maytansine and cellular metabo ...... ics by binding to microtubules
@ast
Maytansine and cellular metabo ...... ics by binding to microtubules
@en
type
label
Maytansine and cellular metabo ...... ics by binding to microtubules
@ast
Maytansine and cellular metabo ...... ics by binding to microtubules
@en
prefLabel
Maytansine and cellular metabo ...... ics by binding to microtubules
@ast
Maytansine and cellular metabo ...... ics by binding to microtubules
@en
P2093
P2860
P1476
Maytansine and cellular metabo ...... ics by binding to microtubules
@en
P2093
Emin Oroudjev
Leslie Wilson
Mary Ann Jordan
Ravi Chari
Sharon Wilhelm
Wayne Widdison
P2860
P304
P356
10.1158/1535-7163.MCT-10-0644
P50
P577
2010-10-01T00:00:00Z